S-3304 in Treating Patients With Advanced Solid Tumors

Phase 1 Completed Roswell Park Cancer Institute

Treatment

Summary

RATIONALE: S-3304 may stop or slow the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of S-3304 in treating patients who have solid tumors.

Timeline

Start: 2001-10
Primary completion: 2002-12
Completion: 2003-01

Publications

Results Chiappori AA, Eckhardt SG, Bukowski R, Sullivan DM, Ikeda M, Yano Y, Yamada-Sawada T, Kambayashi Y, Tanaka K, Javle MM, Mekhail T, O'bryant CL, Creaven PJ. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res. 2007 Apr 1;13(7):2091-9. doi: 10.1158/1078-0432.CCR-06-1586.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	S-3304	Small molecule	800 mg	Oral
Subject	S-3304	Small molecule	1600 mg	Oral
Subject	S-3304	Small molecule	2400 mg	Oral
Subject	S-3304	Small molecule	3200 mg	Oral

S-3304 in Treating Patients With Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications